AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Zivo Bioscience, Inc. Kicks Off Final Phase Of Bovine Mastitis Study September 10, 2017 BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And To Accelerate Knowledge Platform Development May 8, 2017 Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague January 30, 2018
BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And To Accelerate Knowledge Platform Development May 8, 2017
